EDGAR Filing Documents for 0001129928-13-000016

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]:

SEC Accession No. 0001129928-13-000016

Filing Date

2013-03-22

Accepted

2013-03-22 17:17:11

Documents

Period of Report

2012-12-31

Document Format Files

Seq	Description	Document	Type	Size
1	20-F	oncy2012-20f.htm	20-F	1778356
2	MD&A	ex151-2012mda.htm	EX-15.1	447415
3	EY CONSENT	ex1522013eyconsentletter.htm	EX-15.2	4770
4	COFFEY EEA	ex420coffeyexecutiveemploym.htm	EX-4.20	66746
5	TUCHMAN EEA	ex421tuchmanemploymentagree.htm	EX-4.21	75961
6	LOOK EEA	ex422lookexecutiveemploymen.htm	EX-4.22	66318
7	THOMPSON EEA	ex423thompsonexecutiveemplo.htm	EX-4.23	66907
8	SUBSIDIARIES	ex80listofsubsidiaries2012.htm	EX-8.0	4393
9	CEO CERT	oncy-ex121ceocert.htm	EX-12.1	14710
10	CFO CERT	oncy-ex122cfocert.htm	EX-12.2	13432
11	CEO CERT	oncy-ex131ceocert.htm	EX-13.1	7236
12	CFO CERT	oncy-ex132cfocert.htm	EX-13.2	6146
13		eysignature2013.jpg	GRAPHIC	11104
14		reovirusa02.jpg	GRAPHIC	86821
15		finalonclogo.jpg	GRAPHIC	32654
	Complete submission text file	0001129928-13-000016.txt		2733701

Mailing Address 210 - 1167 KENSINGTON CRES NW CALGARY A0 T2N 1X7

Business Address 1167 KENSINGTON CRES NW SUITE 210 CALGARY ALBERTA CANADA T2N 1X7 ALBERTA CANADA A0 00000 4036707380

ONCOLYTICS BIOTECH INC (Filer) CIK: 0001129928 (see all company filings)

IRS No.: 000000000 | Fiscal Year End: 1231
Type: 20-F | Act: 34 | File No.: 000-31062 | Film No.: 13712109
SIC: 2834 Pharmaceutical Preparations